Oncology and Hematology

151-165 of 290

• 

  RestartResume

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  MinuteCE®

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  • 

    

    Fortunato Ciardiello, MD, PhD

    Peer

  • 

    

    Jenny Seligmann, MBChB, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  MinuteCE®

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

  MinuteCE®

  Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

  MinuteCE®

  Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

  MinuteCE®

  The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC

  MinuteCE®

  Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC

  • 

    

    Fortunato Ciardiello, MD, PhD

    Peer

  • 

    

    Jenny Seligmann, MBChB, PhD

    Peer

  1.00 program credits
• advertisement

• 

  RestartResume

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  CME/CE

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

    Peer

  • 

    

    Shilpa Gupta, MD

    Peer

  0.50 credits

• 

  RestartResume

  Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

  CME/CE

  Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

  • 

    

    Aditya Bardia, MD

    Peer

  • 

    

    Tiffany Traina, MD, FASCO

    Peer

  0.25 credits

• 

  RestartResume

  Collaborative Insights to Solve the Puzzle of Bladder Cancer

  CME/CE

  Collaborative Insights to Solve the Puzzle of Bladder Cancer

  • 

    

    Daniel P. Petrylak, MD

    Peer

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

    Peer

  • 

    

    Evan Y. Yu, MD

    Peer

  1.00 credits

• 

  RestartResume

  Personalizing Care Within the RCC Treatment Paradigm

  CME/CE

  Personalizing Care Within the RCC Treatment Paradigm

  • 

    

    Eric Jonasch, MD

    Peer

  • 

    

    Brad McGregor, MD

    Peer

  • 

    

    Ulka Vaishampayan, MBBS

    Peer

  1.00 credits

• 

  MinuteCE®

  The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 credits 4 episodes

• 

  MinuteCE®

  Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician

  • 

    

    Sandra Swain, MD

    Peer

  • 

    

    Virginia Kaklamani, MD

    Peer

  0.50 credits 4 episodes
• advertisement

• 

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  MinuteCE®

  Differential Diagnosis of Indolent Systemic Mastocytosis

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  MinuteCE®

  Is it Nonresponsive/Progressive ISM?

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  MinuteCE®

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• Prev
• 1
• 2
• …
• 9
• 10
• 11
• 12
• 13
• …
• 19
• 20
• Next